================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
-------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 3, 2004
KERYX BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 000-30929 13-4087132
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
750 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrant's telephone number, including area code)
================================================================================
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 3, 2004, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a
press release announcing results of operations for the second quarter ended June
30, 2004. Keryx also announced that it would host a conference call on August
5, 2004, for investors where Keryx will discuss its results of operations and
financial results, as well as the clinical programs for certain of its drug
candidates. A copy of such press release is being furnished as Exhibit 99.1 to
this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
KERYX BIOPHARMACEUTICALS, INC.
(Registrant)
Date: August 3, 2004
By: /s/ Ron Bentsur
--------------------------
Ron Bentsur
Vice President Finance and
Investor Relations
INDEX TO EXHIBITS
EXHIBIT
NUMBER DESCRIPTION
------ -----------
99.1 Press Release dated August 3, 2004.